{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:02:36Z","timestamp":1779692556020,"version":"3.53.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011840","name":"Shantou University Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011840","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Carbapenem-resistant\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      (CRAB) is a leading cause of hospital-acquired infection among critically ill patients, with extremely limited therapeutic options, particularly for central nervous system (CNS) infections. Eravacyline, a novel fully synthetic fluorocycline, demonstrates potent\n                      <jats:italic>in vitro<\/jats:italic>\n                      activity against CRAB but exhibits poor penetration across the blood\u2013brain barrier (BBB).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 17-years-old female with severe traumatic brain injury developed concurrent intracranial, pulmonary, and bloodstream CRAB infections. Initial systemic antimicrobial therapy, including intravenous colistin and eravacycline, failed to control the intracranial infection. After switching to a regimen incorporating intrathecal eravacycline (initial dose 2 mg, followed by 5 mg daily) combined with high-dose intravenous cefoperazone-sulbactam and nebulized colistin, the patient showed rapid clinical and microbiological improvement. Serial cerebrospinal fluid (CSF) metagenomic next-generation sequencing (mNGS) revealed a dramatic reduction in pathogen load, with eventual eradication of CRAB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the potential role of intrathecal eravacycline as a salvage therapy for CRAB meningitis, particularly in cases of multifocal, extensively drug-resistant infection. Further pharmacokinetic and safety studies are warranted to optimize its use in CNS infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1829527","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:04:33Z","timestamp":1779689073000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intrathecal combined with intravenous eravacycline for the treatment of multisite carbapenem-resistant Acinetobacter baumannii infections (intracranial, pulmonary, and bloodstream) in a post-trauma adolescent female: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Jieluan","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Shantou University Medical College, Shantou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Shantou University Medical College, Shantou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbing","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Shantou University Medical College, Shantou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Shantou University Medical College, Shantou","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3171\/2016.10.JNS16379","article-title":"Development of a prediction rule for diagnosing postoperative meningitis: a cross-sectional study.","volume":"128","author":"Hern\u00e1ndez Ortiz","year":"2018","journal-title":"J Neurosurg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.3171\/2013.6.JNS122126","article-title":"Intraventricular and lumbar intrathecal administration of antibiotics in postneurosurgical patients with meningitis and\/or ventriculitis in a serious clinical state.","volume":"119","author":"Reme\u0161","year":"2013","journal-title":"J Neurosurg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","article-title":"Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study.","volume":"3","author":"Pascale","year":"2021","journal-title":"JAC Antimicrob Resist."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e0214221","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e0027924","DOI":"10.1128\/cmr.00279-24","article-title":"Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen.","volume":"38","author":"Dubey","year":"2025","journal-title":"Clin Microbiol Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society.","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"2017 infectious diseases society of America\u2019s clinical practice guidelines for healthcare-associated Ventriculitis and meningitis.","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"6619","DOI":"10.1128\/AAC.00997-16","article-title":"Population pharmacokinetics and dosing regimen optimization of meropenem in cerebrospinal fluid and plasma in patients with meningitis after neurosurgery.","volume":"60","author":"Lu","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020.","volume":"33","author":"Hawser","year":"2023","journal-title":"J Glob Antimicrob Resist."},{"key":"B11","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/1120009X.2021.2005755","article-title":"In vitro and in vivo comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant Acinetobacter baumannii.","volume":"34","author":"Yin","year":"2022","journal-title":"J Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/sur.2024.063","article-title":"Intrathecal tigecycline in the treatment of hospital-acquired meningitis: a review of four cases.","volume":"25","author":"Sanl\u0131da\u011f I\u015fbilen","year":"2024","journal-title":"Surg Infect."},{"key":"B13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3892\/etm.2024.12781","article-title":"Efficacy of intravenous plus intrathecal\/intracerebral ventricle injection of tigecycline for post-neurosurgical intracranial infections due to MDR\/XDR Acinetobacter baumannii: a retrospective cohort study.","volume":"29","author":"Tian","year":"2025","journal-title":"Exp Ther Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1128\/AAC.00275-18","article-title":"Pharmacokinetics and comprehensive analysis of the tissue distribution of eravacycline in rabbits.","volume":"62","author":"Petraitis","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1174","DOI":"10.1128\/AAC.01174-18","article-title":"Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline.","volume":"62","author":"Newman","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3390\/pharmaceutics13122085","article-title":"The development of third-generation tetracycline antibiotics and new perspectives.","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics."},{"key":"B17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/antibiotics13030258","article-title":"Intrapulmonary and systemic pharmacokinetics of colistin following nebulization of low-dose colistimethate sodium in patients with ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.","volume":"13","author":"Lee","year":"2024","journal-title":"Antibiotics."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jiph.2023.05.024","article-title":"Short versus long course of colistin treatment for carbapenem-resistant A. baumannii in critically ill patients: a propensity score matching study.","volume":"16","author":"Katip","year":"2023","journal-title":"J Infect Public Health."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e54652","DOI":"10.7759\/cureus.54652","article-title":"Retrospective observational study to assess safety and tolerability of nebulized colistin for the treatment of patients with pneumonia in real-world settings in respiratory ICU.","volume":"16","author":"Talwar","year":"2024","journal-title":"Cureus."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1395260","DOI":"10.3389\/fcimb.2024.1395260","article-title":"Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii.","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Cell Infect Microbiol."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections.","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1186\/s12879-025-11205-w","article-title":"Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study.","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Infect Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/antibiotics13090907","article-title":"Comparing the outcomes of Cefoperazone\/Sulbactam-Based and Non-Cefoperazone\/sulbactam-based therapeutic regimens in patients with multiresistant Acinetobacter baumannii infections-A meta-analysis.","volume":"13","author":"Huang","year":"2024","journal-title":"Antibiotics."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0335524","DOI":"10.1128\/spectrum.03355-24","article-title":"Evaluation of the efficacy of sulbactam combination therapy for monomicrobial and polymicrobial pulmonary infections caused by multidrug-resistant Acinetobacter baumannii.","volume":"13","author":"Peng","year":"2025","journal-title":"Microbiol Spectr."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1829527\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:04:34Z","timestamp":1779689074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1829527\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":24,"alternative-id":["10.3389\/fmed.2026.1829527"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1829527","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1829527"}}